LACK OF B7 EXPRESSION, NOT HUMAN LEUKOCYTE ANTIGEN EXPRESSION, FACILITATES IMMUNE EVASION BY HUMAN MALIGNANT GLIOMAS
- 1 June 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurosurgery
- Vol. 60 (6), 1129-1136
- https://doi.org/10.1227/01.neu.0000255460.91892.44
Abstract
Lack of human leukocyte antigens and costimulatory molecules have been suggested as mechanisms by which human malignant gliomas avoid immune recognition and elimination. Using quantitative multiparameter flow cytometric analysis, tumor cells from patients with glioblastoma multiforme (n = 18) were examined ex vivo for the expression of human leukocyte antigen Class I and II molecules and the costimulatory molecules B7-1 and B7-2. They were compared with reactive astrocytes from peritumoral brain metastases (n = 7), and astrocytes removed during nontumor surgery (n = 5). In contrast to the vast majority of solid peripheral human tumors, these results demonstrate that glioblastoma multiforme frequently express both human leukocyte antigen Class I and II molecules. Like most solid peripheral tumors, glioblastoma multiforme tumor cells express few or no B7 costimulatory molecules. Functional assays using heterogeneous ex vivo tumor preparations or pure populations of ex vivo tumor cells and microglia obtained using fluorescence-activated cell sorting indicate that CD4+ T-cells are activated by tumor cells only in the presence of exogenous B7 costimulation (provided by addition of soluble agonist anti-CD28 monoclonal antibody). Thus, in contrast to many solid peripheral tumors, failure to present tumor antigens is not a likely impediment to immunotherapeutic strategies against malignant gliomas. Rather, immunotherapeutic strategies need to overcome low levels of B7 costimulation.Keywords
This publication has 33 references indexed in Scilit:
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004
- MHC class I antigens, immune surveillance, and tumor immune escapeJournal of Cellular Physiology, 2003
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- Changes in the Immunologic Phenotype of Human Malignant Glioma Cells after Passaging in VitroClinical Immunology, 2002
- Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN‐γ‐inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4+ T‐cell activationGlia, 2001
- B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicityGene Therapy, 2000
- Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-γ, interleukin-7, or B7-1-transfected tumor cellsCancer Gene Therapy, 1999
- Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse–Human Glioblastoma Multiforme ModelHuman Gene Therapy, 1997
- T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.The Journal of Experimental Medicine, 1994
- Relationship of lymphocyte invasion and survival of brain tumor patientsAnnals of Neurology, 1978